Matinas rises on positive data from first two cohorts in meningitis drug study

Matinas BioPharma Holdings

13/09/2021 12:18

** Shares of Matinas BioPharma Holdings Inc  MTNB.A  rise
~7% to $0.88 premarket
    ** Co reports positive data from first two cohorts of
patients in ongoing trial testing its experimental therapy,
MAT2203, for treatment of cryptococcal meningitis (https://refini.tv/3lmpU0u)
    ** Cryptococcal meningitis is a fungal infection and
inflammation of the membranes covering spinal cord and brain
    ** Overall survival was >95% in 40 patients receiving
MAT2203 in cohort two; all 39 patients completing induction with
MAT2203 achieved sterility, with no evidence of breakthrough or
recurrent infections during the first 10 weeks of antifungal
treatment - MTNB
    ** Co says enrollment in cohort three of the trial has
started and is expected to complete by end of 2021
    ** Study is being sponsored by National Institute of Allergy
and Infectious Diseases
    ** Stock down about 39.3% this year, as of last close

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))